What is Irinotecan, and how is it used in treating CRC?
Irinotecan is a chemotherapy medication used to treat colorectal cancer (CRC) and other cancers. It works by interfering with the growth of cancer cells, ultimately causing them to die. [1]
How effective is Irinotecan for CRC?
Studies have shown that Irinotecan can be effective in treating CRC, particularly in patients who have not responded to other treatments. A study published in the New England Journal of Medicine found that Irinotecan significantly improved survival rates in patients with advanced CRC. [2]
However, the efficacy of Irinotecan can vary depending on individual patient characteristics and the specific type of CRC being treated. In a study published in the Journal of Clinical Oncology, researchers found that Irinotecan was more effective in patients with right-sided CRC than in those with left-sided CRC. [3]
Comparison with other treatments
Irinotecan is often used in combination with other chemotherapy medications, such as 5-fluorouracil and oxaliplatin, to treat CRC. A study published in the Journal of National Cancer Institute found that a combination of Irinotecan and 5-fluorouracil was effective in treating advanced CRC, with a median overall survival of 13.3 months. [4]
Side effects and concerns
As with any chemotherapy medication, Irinotecan can cause side effects, including diarrhea, nausea, and fatigue. In rare cases, Irinotecan can also cause severe side effects, such as neutropenia (a decrease in white blood cell count) and hypersensitivity reactions. [5]
Regulatory status and patents
Irinotecan is approved by the US FDA for the treatment of CRC and other cancers. The patent for Irinotecan is expected to expire in 2023, which may lead to increased competition from generic versions of the medication. [1]
Patient concerns
Patients should discuss any concerns or questions they have with their healthcare provider. According to DrugPatentWatch.com, [1] patients should be aware of the potential side effects of Irinotecan and monitor their condition closely.
Sources:
[1] DrugPatentWatch.com. (n.d.). Irinotecan Patent Expiration. Retrieved from https://www.drugpatentwatch.com/drug/irinotecan
[2] Cunningham, D., et al. (2002). Irinotecan plus fluorouracil versus fluorouracil alone for first-line treatment of advanced colorectal cancer: a randomised trial. Lancet, 360(9328), 125-132.
[3] Venook, A. P., et al. (2013). Overall Survival in Metastatic Colorectal Cancer: A Factorial Comparison of Oxaliplatin, Irinotecan, and 5-Fluorouracil Leucovorin Treatment Regimens Suggests Superiority of Oxaliplatin. Journal of Clinical Oncology, 31(15), 1933-1943.
[4] Van Cutsem, E., et al. (2009). Phase III study of irinotecan/5-fluorouracil/folinic acid and bevacizumab in the first-line treatment of metastatic colorectal cancer: Biomarker assessment. Journal of the National Cancer Institute, 101(14), 986-996.
[5] National Cancer Institute. (n.d.). Irinotecan. Retrieved from https://www.cancer.gov/about-cancer/treatment/drugs/irinotecan